Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer
Objective: To analyze adverse reactions in patients with nonmetastatic colorectal cancer due to treatment with either innovative or generic capecitabine and/or to the chemotherapeutic regimen employed, to the capecitabine alone, or in combination with oxaliplatin (XELOX). Method: Descriptive retrosp...
Saved in:
Main Authors: | Julia Sánchez-Gundín (Author), Ana Isabel Torres-Suárez (Author), Ana María Fernández-Carballido (Author), Dolores Barreda-Hernández (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients
by: Yasmin Cura, et al.
Published: (2023) -
Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023) -
Functionality of innovative and generic celluloses in metronidazole formulations
by: Carmen Cristina Díaz Ramírez, et al.
Published: (2011) -
Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
by: Saeed Alqahtani, et al.
Published: (2022) -
CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010)